Frontal Fibrosing Alopecia: Diagnosis, Monitoring, and Multimodal Treatment Strategies

Conclusions

• Frontal fibrosing alopecia is a common, rising, and likely underrecognized scarring alopecia that primarily affects postmenopausal women.
• The disease is chronic and irreversible, so the main treatment objective is stabilization of progression rather than regrowth.
• Early diagnosis is critical because prompt treatment may help prevent permanent hairline loss and eyebrow destruction.
• FFA appears to involve genetic susceptibility, autoimmune dysregulation, JAK/STAT-related inflammatory pathways, and possible environmental triggers.
• Disease can remain active even when visible redness or scale is absent, making regular monitoring with trichoscopy, serial photography, and scoring systems essential.
• Inflammation control is a central therapeutic goal, using topical agents, intralesional corticosteroids, and systemic anti-inflammatory medications when needed.
• Oral dutasteride and other 5-alpha reductase inhibitors are presented as the strongest or gold-standard option for preventing progression.
• JAK inhibitors, both topical and oral, are emerging therapies with encouraging early results in refractory disease.
• Symptom relief and cosmetic improvement often require adjunctive measures such as minoxidil, naltrexone, gabapentin, isotretinoin, PRP, micropigmentation, or hair restoration in stable cases.
• Hair transplantation should only be considered after prolonged disease inactivity, because operating on active disease may trigger relapse.
• Patient education, long-term adherence, sun-protection strategies, and psychosocial support are important parts of management.
• Overall, the presentation concludes that FFA care should be long-term, multimodal, and individualized, with objective monitoring and early use of effective anti-progressive therapy.